Limeres Jacobo, Sanromán Jacinto F, Tomás Inmaculada, Diz Pedro
Special Needs Unit, School of Medicine and Dentistry, Santiago de Compostela University, Santiago de Compostela, Spain.
J Oral Maxillofac Surg. 2009 Feb;67(2):286-91. doi: 10.1016/j.joms.2008.06.061.
To analyze the impact of the postoperative administration of moxifloxacin (MXF) on oral function and quality of life after third molar (TM) surgery.
A single-center, prospective, randomized, double-blind, controlled clinical trial was designed. The study population consisted of 100 patients who underwent impacted TM extractions. Patients were distributed into 2 groups of 50 individuals each. Postoperatively, one group was administered MXF (400 mg/24 hours for 5 days); the positive control group received amoxicillin and clavulanic acid (AMX-CLV) (500/125 mg/8 hours for 5 days). Follow-up was performed for 7 postoperative days, during which the patient recorded information on pain, the use of rescue analgesia, undesirable effects of the medication, difficulty in speaking, difficulty in chewing, diet consistency, difficulty performing oral hygiene, asthenia, time in bed, going out of the house, and returning to work.
The administration of MFX was significantly associated with headache, and AMX-CLV was significantly associated with diarrhea. Greater difficulty in chewing and performing oral hygiene was observed in the AMX-CLV group compared with the MXF group. The percentage of patients who tolerated a diet of normal consistency was significantly higher in the MXF group compared with the AMX-CLV group. During the first 4 days of follow-up, the percentage of patients who returned to work was significantly higher in the MXF group than in the AMX-CLV group.
Moxifloxacin shortens the period of postoperative recovery in terms of oral function and return to work. Therefore, MXF could be a useful option in TM surgery when antibiotics are indicated, particularly if patients are allergic to beta-lactams, their oral flora is resistant to macrolides, or they are intolerant of either of these antibiotics.
分析莫西沙星(MXF)术后给药对第三磨牙(TM)手术后口腔功能和生活质量的影响。
设计了一项单中心、前瞻性、随机、双盲、对照临床试验。研究人群包括100例行埋伏阻生TM拔除术的患者。患者被分为两组,每组50人。术后,一组给予MXF(400mg/24小时,共5天);阳性对照组接受阿莫西林克拉维酸(AMX-CLV)(500/125mg/8小时,共5天)。术后随访7天,在此期间患者记录疼痛、使用解救镇痛药、药物不良反应、说话困难、咀嚼困难、饮食稠度、口腔卫生执行困难、乏力、卧床时间、出门和恢复工作等信息。
服用MFX与头痛显著相关,服用AMX-CLV与腹泻显著相关。与MXF组相比,AMX-CLV组在咀嚼和执行口腔卫生方面困难更大。与AMX-CLV组相比,MXF组能够耐受正常稠度饮食的患者百分比显著更高。在随访的前4天,MXF组恢复工作的患者百分比显著高于AMX-CLV组。
莫西沙星在口腔功能和恢复工作方面缩短了术后恢复时间。因此,在TM手术中,当需要使用抗生素时,尤其是患者对β-内酰胺类过敏、口腔菌群对大环内酯类耐药或不耐受这两种抗生素时,MXF可能是一个有用的选择。